Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Bristol’s Integration Strategy With Celgene Includes “Ring-Fencing” Oncology Teams

Firm hopes to minimize merger disruption by maintaining separate BMS, Celgene cancer expertise. Opdivo posts solid growth, but longer-term worries persist.

Sales & Earnings Commercial ImmunoOncology

AbbVie CEO Upbeat On Skyrizi Commercialization, Raises Financial Guidance

AbbVie’s product pipeline may be delivering just in time to alleviate concerns about loss of exclusivity on its best-selling product, Humira.

 

Commercial Companies Sales & Earnings

Divest, Refocus, Transition: Multinationals Embark On Uncharted Path In China

Facing unprecedented pricing pressures in China, multinationals are embarking on a major shift away from mature products to focus more on innovative drugs, but there are major challenges linked to the transition that won’t be easy to navigate, notes a new report.

China Business Strategies Commercial
Advertisement


 Recent Tweets from Scrip


Embedding Time-Critical Scheduling in Drug Production

Manufacturing is the engine room of the pharmaceutical industry. Ultimately, a medicine has little value if it does not reach patients on schedule, in the required quantity and quality. Download this whitepaper which discusses time-critical scheduling in drug production.

Download Whitepaper
Advertisement

 

Commercial Explore this Topic

Set Alert for Commercial

China Pharma Sales Bring Bayer Relief From Monsanto Legal Woes

Xarelto and Eylea are continuing to sell well but the German major faces another heap of litigation in the US over Monsanto's weedkillers which is alarming shareholders.

Companies Sales & Earnings Legal Issues

Taltz Results In Spondyloarthritis Add To Lilly Franchise Hopes

Taltz has sailed through the latest trial in Lilly’s COAST program, in non-radiographic axial spondyloarthritis, but choppy waters may be ahead; meanwhile, Lilly signs an immunology deal with Avidity Biosciences.

Clinical Trials Inflammation Deals

AbbVie’s Humira Succession Plan Begins Taking Shape With Skyrizi US Approval

Central to AbbVie’s plans to endure biosimilar erosion to Humira, Skyrizi gets US approval in psoriasis, with approval of upadacitinib expected in RA this year.

Approvals Business Strategies

Biogen Stays Steady As Alzheimer’s Programs Falter

Still reeling from aducanumab’s failure in Phase III Alzheimer’s trial, Biogen management played up the company’s progress toward diversification and the promise of its pipeline. 
Sales & Earnings Biosimilars

Piramal’s Sensipar Generic Blocked In US, For Now

Piramal halted sales of its generic version of Amgen’s Sensipar following a US court order that also required Amgen to furnish a $39m bond. The Sensipar generic launch landscape continues to be complex with multiple legal challenges, including those from Cipla and Sun at various stages.

Generic Drugs Legal Issues

Novartis CEO Issues Staunch Defense of Zolgensma As Sales Soar

The Swiss major has got off to a strong start in 2019 with Cosentyx and Entresto sales soaring and Mayzent – and possibly very soon Zolgensma – getting US approvals.

Sales & Earnings Companies

Hepalink-Backed HighTide Bets On NASH For Global Markets

Emerging Company Profile: Fatty liver disease has been a hot development area that keeps getting more attention, and one Chinese startup backed by the world’s largest heparin manufacturer is looking to launch a new therapy globally.


China Liver & Hepatic

Bristol’s Focus Returns To IO Following Celgene Vote

Q1 Earnings Preview: With the positive vote on its merger with Celgene behind it, Bristol now needs to focus on growing its immuno-oncology business, where several upcoming catalysts could bolster Opdivo.

Sales & Earnings Business Strategies

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Lilly’s Lartruvo Withdrawal Stirs Questions About Payment For Accelerated Approval Drugs

News that the soft tissue sarcoma drug will come off the market after its confirmatory trial failed to verify clinical benefit spurs Memorial Sloan-Kettering’s Peter Bach to ask whether Lilly will refund money to payers.

Reimbursement Pricing Debate Review Pathway

India New Trial Rules - Sponsors Interested But 'FAQ' Could Help

India’s new clinical trial regulations could revive sponsor interest in the country, but some norms around local Phase III trial waivers appear open to interpretation and could potentially weigh down momentum.

Clinical Trials India

Gelesis's Obesity Product FDA Acceptance Gives Boost To PureTech's Portfolio


PureTech's affiliate Gelesis has received FDA clearance for its Plenity capsule to treat overweight-obese adults, and plans to launch it commercially in the second half. 
Approvals Metabolic Disorders

Insulin Assistance Programs: Big Help Or Just A Band-Aid?

Drug makers and other stakeholders have been rolling out insulin savings programs as the high cost of insulins come under scrutiny on Capitol Hill. Sanofi announced an expanded cost-savings program during a House hearing, but one Congresswoman called them a band-aid. 

Pricing Debate Policy & Regulation

Research & Development Explore this Topic

Set Alert for Research & Development

Another NASH Failure: Gilead’s Hits Keep Coming

The failure of the STELLAR-3 trial of selonsertib had been widely anticipated following the failure in a sicker population in STELLAR-4.
Clinical Trials Metabolic Disorders Liver & Hepatic

BIO-Europe Spring 2019: Sterna CEO On Raising Cash For Pipeline Progress

During BIO-Europe Spring 2019, Christian Pangratz, CEO of sterna biologicals, talks to Lucie Ellis, executive editor of In Vivo, about the company's pipeline of immunology-focused assets. 

Companies Research and Development Strategies

Teva’s Ajovy Failure In Cluster Headaches Good For Lilly’s CGRP Inhibitor Emgality

Lilly's Emgality looks set to benefit from Teva ending clinical development of its CGRP antibody competitor in cluster headaches due to lack of efficacy in Phase III.

Clinical Trials Companies

The 2019 Worldwide Pharma & Biotech Industry R&D Scene

INFOGRAPHIC: A snapshot of the industry in key performance indicators, taken in early 2019.

 

Market Intelligence Research & Development
UsernamePublicRestriction

Register

Advertisement